8
Total investments
1
Early stage
3
Mid stage
0
Late stage
5y
Years active
Portfolio
7 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
May 2026
ReviMo creates robotic mobility devices to help people with limited mobility to take care of themselves independently and reduce the burden on caregivers. Techstars portfolio company.
Seed Investor
Mar 2026
NGS Product Development with focuses on liquid biopsy and precision medicine. Specifically, we aim to provide NGS library preparation solution with no "writing" or "erasing", and maximize sample information in its native state.
Seed Investor
Nov 2025
Akeynas mission is to improve the lives of patients and physicians with our innovative smart needle medical technology. Please contact us to learn more.
Investor
Nov 2025
ClearCut Surgical was created by surgeons for surgeons to solve a universally frustrating operating room problem: how to manage fluid buildup during tissue electrocautery. Through surgeon-driven innovation, ClearCut has developed a novel electrocautery surgical tool with continuous smoke evacuation and on-demand fluid suction.
Investor
Aug 2025
Gaia AI is an MIT & Harvard startup using LiDAR, computer vision, and satellite data to collect high-quality biomass data in forests, helping land owners, project developers, and investors understand the carbon stock and timber content of their land. By measuring the carbon content of a forest with high accuracy, we give carbon credit buyers confidence that their credit was backed by a ton of carbon sequestered, and thus create trust in and help unlock the carbon credit market.
Investor
Jun 2025
We are making a simple blood test to differentiate and quantify nearly all pathogen genes in hospitalized patients. Pathogen DNA is detectable at early stages of infection, and by quantifying it over time, we aim to change how infections are managed at every phase of care.
The solution is “hidden in plain sight.” We enhance digital PCR hardware that hospitals are already starting to adopt with machine learning and programmable chemistry. Today, PCR tests have become routine but only for limited sets of pathogens. By making PCR both comprehensive and extremely sensitive, we will detect the range of pathogen genes at the "helix in the haystack" levels found in blood.
Seed Investor, Advisor
Jan 2021
Capra Biosciences is developing a new technology that will make the manufacturing of chemicals using biology cost-competitive with petroleum-based products. Significant advances in synthetic biology have been made over the past 20 years, enabling a multitude of products with lower environmental impact and potentially better performance than their petrochemical counterparts. However, cost-competitive large-scale manufacturing of these products remains a significant bottleneck to their adaptation. Our technology tackles this bottleneck through an innovative bioreactor design that promises to significantly reduce end-to-end manufacturing costs.
Experience · 10 entries
All (10)
Investments (8)
Board (1)
2026
Board Member
May 2026
ReviMo creates robotic mobility devices to help people with limited mobility to take care of themselves independently and reduce the burden on caregivers. Techstars portfolio company.
Seed Investor
Mar 2026
NGS Product Development with focuses on liquid biopsy and precision medicine. Specifically, we aim to provide NGS library preparation solution with no "writing" or "erasing", and maximize sample information in its native state.
Limited Partner
Jan 2026
Historically, there has been a significant lack of attention given to accessibility and disability technology companies by investors. Almost everyone experiences some type of disability during their lifetime, whether permanent or temporary.
The massive market opportunity, returns, and impact that such startups can have globally when given the right tools, support, and funding has been overlooked, misunderstood, and underestimated for far too long.
Adaptation Ventures is an angel group that funds founders building scalable, accessible solutions that benefit the disability community. We help unleash important innovations into the world’s largest overlooked market.
2025
Seed Investor
Nov 2025
Akeynas mission is to improve the lives of patients and physicians with our innovative smart needle medical technology. Please contact us to learn more.
Investor
Nov 2025
ClearCut Surgical was created by surgeons for surgeons to solve a universally frustrating operating room problem: how to manage fluid buildup during tissue electrocautery. Through surgeon-driven innovation, ClearCut has developed a novel electrocautery surgical tool with continuous smoke evacuation and on-demand fluid suction.
Show all 10 entries ↓
Investment activity
2021–2026 · 8 investments
Recent (last 2 years)Earlier
